These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 20670206)

  • 1. Safety evaluation of tirofiban.
    Valgimigli M; Tebaldi M
    Expert Opin Drug Saf; 2010 Sep; 9(5):801-19. PubMed ID: 20670206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tirofiban for myocardial infarction.
    Juwana YB; Suryapranata H; Ottervanger JP; van 't Hof AW
    Expert Opin Pharmacother; 2010 Apr; 11(5):861-6. PubMed ID: 20210689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
    Dorsch MP; Montague D; Rodgers JE; Patterson C
    Pharmacotherapy; 2006 Mar; 26(3):423-7. PubMed ID: 16503724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
    Hermanides RS; Ottervanger JP; ten Berg JM; Gosselink AT; van Houwelingen G; Dambrink JH; Stella PR; Hamm C; van 't Hof AW;
    J Invasive Cardiol; 2012 Mar; 24(3):84-9. PubMed ID: 22388296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
    Stone GW; Moliterno DJ; Bertrand M; Neumann FJ; Herrmann HC; Powers ER; Grines CL; Moses JW; Cohen DJ; Cohen EA; Cohen M; Wolski K; DiBattiste PM; Topol EJ
    Circulation; 2002 May; 105(20):2347-54. PubMed ID: 12021219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.
    Dasgupta H; Blankenship JC; Wood GC; Frey CM; Demko SL; Menapace FJ
    Am Heart J; 2000 Aug; 140(2):206-11. PubMed ID: 10925331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial.
    Berger PB; Best PJ; Topol EJ; White J; DiBattiste PM; Chan AW; Kristensen SD; Herrmann HC; Moliterno DJ
    Am Heart J; 2005 May; 149(5):869-75. PubMed ID: 15894970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.
    Gunasekara AP; Walters DL; Aroney CN
    Int J Cardiol; 2006 Apr; 109(1):16-20. PubMed ID: 16014315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study.
    Moliterno DJ; Topol EJ
    Am Heart J; 2000 Nov; 140(5):722-6. PubMed ID: 11054616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of 2 platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].
    Rossi ML; Merlini PA
    Ital Heart J Suppl; 2001 Oct; 2(10):1130-2. PubMed ID: 11723620
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment with tirofiban for acute coronary syndrome (ACS): a systematic review and network analysis.
    Lang SH; Manning N; Armstrong N; Misso K; Allen A; Di Nisio M; Kleijnen J
    Curr Med Res Opin; 2012 Mar; 28(3):351-70. PubMed ID: 22292469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycoprotein IIb/IIIa inhibitors in patients with renal insufficiency undergoing percutaneous coronary intervention.
    Anderson JR; Riding D
    Cardiol Rev; 2008; 16(4):213-8. PubMed ID: 18562812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban).
    Assali AR; Salloum J; Sdringola S; Moustapha A; Ghani M; Hale S; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR
    Am J Cardiol; 2001 Oct; 88(8):884-6, A6. PubMed ID: 11676953
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
    Sabatine MS; Jang IK
    Am J Med; 2000 Aug; 109(3):224-37. PubMed ID: 10974186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.
    Bolognese L; Falsini G; Liistro F; Angioli P; Ducci K; Taddei T; Tarducci R; Cosmi F; Baldassarre S; Burali A
    J Am Coll Cardiol; 2006 Feb; 47(3):522-8. PubMed ID: 16458130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty.
    Chen YH; Chen JW; Wu TC; Ding PY; Wang SP; Chang MS
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan; 63(1):8-15. PubMed ID: 10645045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.